Gufic BioScience

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE742B01025
NSEID: GUFICBIO
BSEID: 509079

INR

347.25

-2 (-0.57%)

BSENSE

Dec 19

BSE+NSE Vol: 20.41 k

{
  "main_header": {
    "sid": 338998,
    "name": "Gufic BioScience",
    "stock_name": "Gufic BioScience",
    "full_name": "Gufic BioSciences Ltd",
    "name_url": "stocks-analysis/gufic-bioscience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "347.25",
    "chg": -2,
    "chgp": "-0.57%",
    "dir": -1,
    "prev_price": "349.25",
    "mcapval": "3,520.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 509079,
    "symbol": "GUFICBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE742B01025",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "20.41 k",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gufic-bioscience-338998-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gufic BioScience Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gufic-bioscience-downgraded-to-strong-sell-amid-valuation-and-financial-concerns-3763630",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GuficBioScience_mojoScore_3763630.png",
        "date": "2025-12-19 10:10:48",
        "description": "Gufic BioScience has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a complex interplay of valuation concerns, financial performance, and market sentiment, underscoring the challenges faced by this small-cap stock in a competitive sector."
      },
      {
        "title": "Gufic BioSciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gufic-biosciences-technical-momentum-shifts-amid-mixed-indicator-signals-3759329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GuficBioScience_technicaldot_3759329.png",
        "date": "2025-12-16 08:05:34",
        "description": "Gufic BioSciences, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition in price trends and technical parameters, offering investors a detailed landscape of the stock’s current positioning amid broader market dynamics."
      },
      {
        "title": "Gufic BioSciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gufic-biosciences-faces-bearish-momentum-amid-technical-downgrade-3758239",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GuficBioScience_technicaldot_3758239.png",
        "date": "2025-12-15 08:01:28",
        "description": "Gufic BioSciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious outlook amid broader sector and market dynamics."
      },
      {
        "title": "Gufic BioSciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gufic-biosciences-faces-bearish-momentum-amid-technical-downturn-3755891",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GuficBioScience_technicaldot_3755891.png",
        "date": "2025-12-11 08:03:04",
        "description": "Gufic BioSciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious market stance amid broader sector dynamics and fluctuating investor sentiment."
      },
      {
        "title": "Is Gufic BioScience overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gufic-bioscience-overvalued-or-undervalued-3745251",
        "imagepath": "",
        "date": "2025-12-04 08:18:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Elevated Pricing</strong></p>\n<p>At a price-to-earnings (PE) ratio of 61.6, Gufic BioScience trades at a significant premium compared to many of its pharmaceutical peers. This elevated PE suggests that investors are pricing in strong future growth, but it also implies a higher risk if growth expectations are not met. The price-to-book (P/B) ratio of 5.56 further underscores the premium valuation, indicating that the market values the company at over five times its net asset value.</p>\n<p>Enterprise value (EV) multiples also reflect this expensive stance. The EV to EBIT ratio stands at 36.6, and EV to EBITDA at 28.8, both considerably higher than industry averages. These multiples suggest that the market expects robust earnings before interest and taxes, as well as ..."
      },
      {
        "title": "Gufic BioScience Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gufic-bioscience-downgraded-to-strong-sell-amid-weak-financials-and-valuation-concerns-3735096",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GuficBioScience_mojoScore_3735096.png",
        "date": "2025-11-28 10:05:47",
        "description": "Gufic BioScience, a small-cap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and valuation concerns, impacting investor sentiment and stock performance."
      },
      {
        "title": "Why is Gufic BioScience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gufic-bioscience-fallingrising-3726570",
        "imagepath": "",
        "date": "2025-11-25 00:25:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>On 24 November, Gufic BioSciences closed at ₹354.65, up by ₹1.45 or 0.41%. This uptick is part of a broader short-term rally, with the stock gaining 12.66% over the past week, significantly outperforming the Sensex, which was nearly flat with a marginal decline of 0.06% during the same period. Over the last month, the stock also outpaced the benchmark, delivering a 3.93% return compared to the Sensex’s 0.82% rise.</p>\n<p>Notably, the stock has been on a consecutive five-day gain streak, touching an intraday high of ₹374.20 on the day, marking a 5.95% increase from recent lows. This positive price action has been supported by rising investor participation, with delivery volumes on 21 November increasing by 36.51% compared to the fiv..."
      },
      {
        "title": "Gufic BioSciences Sees Shift in Technical Momentum Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gufic-biosciences-sees-technical-momentum-shift-amid-mixed-market-signals-3723648",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GuficBioScience_technicaldot_3723648.png",
        "date": "2025-11-24 08:01:29",
        "description": "Gufic BioSciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market assessment. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring evolving investor sentiment and market dynamics."
      },
      {
        "title": "Why is Gufic BioScience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gufic-bioscience-fallingrising-3715983",
        "imagepath": "",
        "date": "2025-11-19 21:49:16",
        "description": "As of 19-Nov, Gufic BioSciences Ltd is experiencing a price increase, currently at 335.05, reflecting a rise of 5.35 (1.62%). The stock has shown a positive performance today, outperforming its sector by 1.55% and achieving a consecutive gain over the last two days with a total return of 6.43%. Additionally, the stock reached an intraday high of Rs 348, indicating strong intraday trading activity. The delivery volume has significantly increased, rising by 335.29% against the 5-day average, suggesting heightened investor interest. However, the stock's performance over the past month shows a decline of 4.72%, and it has a year-to-date drop of 26.05%, indicating some underlying challenges despite the recent gains.\n\nIn the broader market context, Gufic BioSciences' short-term return of +1.36% over the past week outperformed the Sensex, which increased by 0.85%. This indicates that while the stock has faced long..."
      }
    ],
    "total": 514,
    "sid": "338998",
    "stock_news_url": "https://www.marketsmojo.com/news/gufic-biosciences-338998"
  },
  "announcements": [
    {
      "caption": "Intimation Of Environmental Social And Governance (ESG) Rating",
      "datetime": "10-Dec-2025",
      "details": "Intimation of ESG Rating is attached herewith",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "21-Nov-2025",
      "details": "Written Transcript of Earnings Conference Call held on November 17 2025 at 04:30 p.m. is attached herewith.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "21-Nov-2025",
      "details": "Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer Requests of Physical Shares is attached herewith",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Gufic BioSciences Ltd has declared <strong>10%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Gufic BioScience Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-12-19 10:10:48

Gufic BioScience has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a complex interplay of valuation concerns, financial performance, and market sentiment, underscoring the challenges faced by this small-cap stock in a competitive sector.

Gufic BioSciences Technical Momentum Shifts Amid Mixed Market Signals

2025-12-16 08:05:34

Gufic BioSciences, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition in price trends and technical parameters, offering investors a detailed landscape of the stock’s current positioning amid broader market dynamics.

Gufic BioSciences Technical Momentum Shifts Amid Mixed Market Signals

2025-12-15 08:01:28

Gufic BioSciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious outlook amid broader sector and market dynamics.

Gufic BioSciences Technical Momentum Shifts Amid Mixed Market Signals

2025-12-11 08:03:04

Is Gufic BioScience overvalued or undervalued?

2025-12-04 08:18:22

Valuation Metrics Indicate Elevated Pricing

At a price-to-earnings (PE) ratio of 61.6, Gufic BioScience trades at a significant premium compared to many of its pharmaceutical peers. This elevated PE suggests that investors are pricing in strong future growth, but it also implies a higher risk if growth expectations are not met. The price-to-book (P/B) ratio of 5.56 further underscores the premium valuation, indicating that the market values the company at over five times its net asset value.

Enterprise value (EV) multiples also reflect this expensive stance. The EV to EBIT ratio stands at 36.6, and EV to EBITDA at 28.8, both considerably higher than industry averages. These multiples suggest that the market expects robust earnings before interest and taxes, as well as ...

Gufic BioScience Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-11-28 10:05:47

Gufic BioScience, a small-cap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and valuation concerns, impacting investor sentiment and stock performance.

Why is Gufic BioScience falling/rising?

2025-11-25 00:25:15

Recent Price Movement and Market Performance

On 24 November, Gufic BioSciences closed at ₹354.65, up by ₹1.45 or 0.41%. This uptick is part of a broader short-term rally, with the stock gaining 12.66% over the past week, significantly outperforming the Sensex, which was nearly flat with a marginal decline of 0.06% during the same period. Over the last month, the stock also outpaced the benchmark, delivering a 3.93% return compared to the Sensex’s 0.82% rise.

Notably, the stock has been on a consecutive five-day gain streak, touching an intraday high of ₹374.20 on the day, marking a 5.95% increase from recent lows. This positive price action has been supported by rising investor participation, with delivery volumes on 21 November increasing by 36.51% compared to the fiv...

Gufic BioSciences Sees Shift in Technical Momentum Amid Mixed Market Signals

2025-11-24 08:01:29

Gufic BioSciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market assessment. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring evolving investor sentiment and market dynamics.

Why is Gufic BioScience falling/rising?

2025-11-19 21:49:16

As of 19-Nov, Gufic BioSciences Ltd is experiencing a price increase, currently at 335.05, reflecting a rise of 5.35 (1.62%). The stock has shown a positive performance today, outperforming its sector by 1.55% and achieving a consecutive gain over the last two days with a total return of 6.43%. Additionally, the stock reached an intraday high of Rs 348, indicating strong intraday trading activity. The delivery volume has significantly increased, rising by 335.29% against the 5-day average, suggesting heightened investor interest. However, the stock's performance over the past month shows a decline of 4.72%, and it has a year-to-date drop of 26.05%, indicating some underlying challenges despite the recent gains. In the broader market context, Gufic BioSciences' short-term return of +1.36% over the past week outperformed the Sensex, which increased by 0.85%. This indicates that while the stock has faced long...

View All News